Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044371 | 0.89 | BACE1 (1.00) | BACE1CYP2D6KCNH2BACE2 | |
| SCHEMBL14889659 | 0.89 | BACE1 (1.00) | BACE1CYP2D6KCNH2 | |
| SCHEMBL14889658 | 0.89 | BACE1 (1.00) | BACE1CYP2D6KCNH2 | |
| SCHEMBL14889814 | 0.88 | BACE1 (0.79) | BACE1CYP2D6KCNH2 | |
| SCHEMBL14889812 | 0.88 | BACE1 (0.79) | BACE1CYP2D6KCNH2 | |
| SCHEMBL18044370 | 0.88 | BACE1 (0.78) | BACE1CYP2D6KCNH2 | |
| SCHEMBL15028651 | 0.87 | BACE1 (0.81) | BACE1CYP2D6KCNH2BACE2 | |
| SCHEMBL16241483 | 0.87 | BACE1 (0.81) | BACE1CYP2D6KCNH2BACE2 | |
| SCHEMBL16241484 | 0.87 | BACE1 (0.81) | BACE1CYP2D6KCNH2BACE2 | |
| SCHEMBL19714244 | 0.86 | BACE1 (1.00) | BACE1CYP2D6KCNH2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828350-B2 | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-28 | — | — | US | claimed |
| EP-2580200-B1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-14 | — | — | EP | claimed |
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2016-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885CYP2D6 3477/4885KCNH2 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.